Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.
Phase 3
Recruiting
- Conditions
- PneumoniaMyocardial Injury
- Interventions
- Drug: TAD® 600 mg/4 mL powder and solvent for solution for injectionDrug: Saline solution 0.9% of sodium chloride
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 178
- Registration Number
- NCT06296212
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Pisana, Pisa, PI, Italy
🇮🇹Fondazione Policlinico Universitario Campus Bio-Medico, Roma, RM, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, RM, Italy
© Copyright 2025. All Rights Reserved by MedPath